Tiziana Life Sciences Ltd · NASDAQ:TLSA
Tiziana Life Sciences — Technical Presentation (November 2026)
20 slides from Tiziana Life Sciences's technical presentation, Nov 9, 2026
Slide 1: INFORMS-MS Phase 2 Trial of Intranasal Foralumab in na-SPMS: KOL Call
INFORMS-MS A Phase 2 Placebo Controlled, Double Blind Trial of Intranasal Foralumab Non-active Secondary Progressive Multiple Sclerosis (na-SPMS) KOL Call November 9th 2026 Nasdaq: TLSA
Slide 2: Forward-Looking Statements and Important Information
2 INFORM-MS KOL Call: Forward-Looking Statements and Important Information Forward-Looking Statements. This presentation may contain forward-looking statements within the meaning of applicable U.S. federal securities laws, including Section 27A of the Securities Act of 1933 and Section 21E of the Se
Slide 3: Meet the Presenters
3 INFORM-MS Virtual KOL Call: Meet the Presenters Tanuja Chitnis, M.D. Principal Investigator of the INFORM-MS trial Professor of Neurology, Harvard Medical School / Brigham and Women's Hospital Tarun Singhal, M.B.B.S, M.D., M.B.A. Founding Director, NeuroPET Program Ann Romney Center for Neurologic
Slide 4: Major Unmet Need in Non-Active SPMS
4 INFORM-MS: Major Unmet Need in Non-Active SPMS • No FDA-approved therapies specifically indicated for non-active SPMS • Patients with progression independent of relapses (PIRA) remain in need of effective therapy • ~25% of RRMS patients progress to SPMS; substantial portion become non-active • Fat
Slide 5: Foralumab: Mechanism of Action
CD4+ FoxP3+ Treg Patient inhales the antibody intranasally Binding of foralumab to the T-cell receptor complex in cervical lymph node Tregs are then created and activated These created Tregs then cross the blood brain barrier and regulate the activated innate immune system (microglia). Intranasal Si
Slide 6: Expanded Access Trial: Intranasal Foralumab in na-SPMS
EXPANDED ACCESS TRIAL Intranasal Foralumab Non-active Secondary Progressive Multiple Sclerosis (na-SPMS)
Slide 7: Positive Results With Nasal Foralumab in Expanded Access Program
7 Positive Results With Nasal Foralumab in Expanded Access Program No Toxicities No treatment-related toxicities observed No anti-drug antibodies detected in serum TSPO PET 8 / 10 Patients Showed Reduced Neuroinflammation After 3 Months Treatment Fatigue 7 / 10 Patients Improved After 6 Months Treat
Slide 8: Nasal Foralumab Reduced Neuroinflammation in Expanded Access Program
8 Nasal Foralumab Reduced Neuroinflammation in Expanded Access Program Neurol Neuroimmunol Neuroinflamm 2026;13:e200543. doi:10.1212/NXI.0000000000200543 Reduced TSPO-PET signal after nasal foralumab treatment. Individualized pGALP z-score maps for patients EA6 (A) and EA1 (B) superimposed on respec
Slide 9: Nasal Foralumab Modulates Immune Function
9 Nasal Foralumab Modulates Immune Function Molecular & Cellular Effects in Blood & CSF of na-SPMS Patients Treated with Nasal Foralumab Results after 6 months nasal foralumab treatment Increase in regulatory T cells (Tregs) Decrease in cytotoxic T cells Reduced inflammation in spinal fluid
Slide 10: INFORMS-MS Topline Data
INFORMS-MS TOPLINE DATA Phase 2 Placebo Controlled, Double Blind Trial of Intranasal Foralumab Confirms Results of EA Program Non-active Secondary Progressive Multiple Sclerosis (na-SPMS)
Slide 11: INFORM-MS: Participant Flow and Evaluable Data
11 INFORM-MS: Participant Flow and Evaluable Data 67 screened 48 randomized Placebo 18 randomized Safety 18 of 18 PET scan pair 15 of 18 MFIS total 17 of 18 EDSS 18 of 18 Foralumab 50 µg 19 randomized Safety 19 of 19 PET scan pair 15 of 19 MFIS total 18 of 19 EDSS 18 of 19 Foralumab 100 µg 11 random
Slide 12: INFORM-MS: Topline Results Overview
12 INFORM-MS: Topline Results Overview Both primary endpoints (TSPO-PET Neuroinflammation and safety) were met. Secondary MFIS endpoint also met. PET Microglial Activation 50 μg vs Placebo p = 0.0168 Statistically significant reduction in TSPO-PET signal demonstrating decreased microglial activation
Slide 13: INFORM-MS: Neuroinflammation Was Statistically Significantly Reduced
13 INFORM-MS: Neuroinflammation Was Statistically Significantly Reduced On ANCOVA analysis, [¹⁸F]PBR06-TSPO PET demonstrated a significant reduction in globally normalized White Matter SUVR (p=0.0168) after 12 weeks of treatment between the 50 ug nasal foralumab treatment arm and placebo. Examples o
Slide 14: INFORM-MS: Nasal Foralumab Reduced Fatigue
14 INFORM-MS: Nasal Foralumab Reduced Fatigue (Lowered Modified Fatigue Impact Scores; "MFIS") MFIS: * p < 0.05 is a within-arm paired t-test; no treatment-versus-placebo comparison is implied (n = 18, 11, 17 with a complete pair). https://www.msard-journal.com/article/S2211-0348(19)30319-0/fulltext
Slide 15: INFORM-MS: Topline Results Overview
15 INFORM-MS: Topline Results Overview Both primary endpoints (TSPO-PET Neuroinflammation and safety) were met. Secondary MFIS endpoint also met. PET Microglial Activation 50 μg vs Placebo p = 0.0168 Statistically significant reduction in TSPO-PET signal demonstrating decreased microglial activation
Slide 16: Intranasal Foralumab Pipeline
16 Intranasal Foralumab Pipeline Nasdaq: TLSA Preclinical IND Phase 1 Expanded Access Program Phase 2 Phase 3 Non-Active Secondary Progressive Multiple Sclerosis Phase 2 Study Positive Topline Data November 2026 Multiple System Atrophy (MSA) Phase 2 Study Expecting Topline Data Q2 2027 Alzheimer's D
Slide 17: Nasal Foralumab Dampens Microglial Activation in Alzheimer's Disease
17 Nasal foralumab dampens microglial activation in Alzheimer's Disease Singhal T, Cicero S, Gale SA, Horan N, Dubey S, Marshall GA, Weiner HL. Dampening of Microglial Activation With Nasal Foralumab Administration in Moderate Alzheimer's Disease Dementia Clin Nucl Med. 2025 Aug 1;50(8):756-757
Slide 18: Nasal Foralumab Reduces Microglial Activation in Multiple System Atrophy
18 Nasal foralumab reduces microglial activation in Multiple System Atrophy Tiziana LifeSciences press releases Marked reduction in basal ganglia uptake following nasal foralumab PRE FORALUMAB POST FORALUMAB PRE FORALUMAB POST FORALUMAB Marked reduction in Cerebellar white matter uptake following na
Slide 19: Questions
Questions Nasdaq: TLSA
Slide 20: US and UK Headquarters Contact Details
US Headquarters (Boston) Tiziana Life Sciences Ltd. 535 Boylston Street, Floor 8 Boston, MA 02116 UK Headquarters (London) Tiziana Life Sciences plc 35a Albemarle Street London W1S 4JE Investors: +44 (0)207 495 2379 info@tizianalifesciences.com Nasdaq: TLSA
Tiziana Life Sciences — Technical Presentation (November 2026) on 6ix